Shares of Sanofi (Nasdaq: SNY) surged in pre-market trading following the announcement of a favorable outcome in an International Chamber of Commerce dispute. 

The tribunal ruled in favor of Sanofi, dismissing Boehringer Ingelheim's indemnification claim and confirming that Sanofi is not liable for potential losses related to the ongoing Zantac litigation in the U.S. This decision is final and cannot be appealed.

Sanofi remains highly confident in its defense against the U.S. Zantac litigation, asserting that the underlying scientific evidence supporting their position is robust. There is no credible scientific data linking Zantac, or its active ingredient ranitidine, to the alleged injuries in the ongoing cases involving GSK plc (NYSE: GSK), Pfizer (NYSE: PFE), Boehringer Ingelhei, Sanofi, and others. 

Both the FDA and the European Medicines Agency have conducted thorough evaluations of the available data and have found no evidence to suggest that ranitidine causes cancer.

In pre-market, $SNY is currently trading at $53.42, up $1.38 (+2.65%).

In another news, Innovative Eyewear, Inc. (Nasdaq: LUCY) has entered into a licensing agreement with Authentic Brands Group, securing a license for the renowned sports culture brand, Reebok, to develop smart eyewear.

Reebok, known for its strong ties to professional sports, sneaker culture, and performance apparel, will now extend its influence to the world of smart eyewear. The anticipated launch of the initial Reebok smart eyewear collection is slated for early 2024, featuring a range of styles designed for both men and women.

$LUCY is currently trading at $3.04, with a notable increase of $0.85 (+38.81%) in pre-market

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)